Australian pharma company De Motu Cordis (DMC), which is developing an epinephrine DPI for the treatment of anaphylaxis, announced that it has contracted with Catalent for product assembly, expanding a November 2022 deal with the CDMO that covered formulation and manufacturing. The extension of the deal will provide manufacturing and assembly services through a … [Read more...] about De Motu Cordis announces expansion of deal with Catalent for services related to development of DMC-IH1 epinephrine DPI
News
FDA issues CRL to Orexo’s resubmitted NDA for OX124 naloxone nasal powder
The FDA has issued a complete response letter to Orexo's NDA for OX124 intranasal dry powder naloxone for the reversal of opioid overdose, the company said. Orexo resubmitted the NDA in September 2023 after the agency rejected its first application due to concerns about the packaging process. The NDA had been initially submitted in early 2023. The FDA accepted the … [Read more...] about FDA issues CRL to Orexo’s resubmitted NDA for OX124 naloxone nasal powder
FDA allows expansion of Phase 2a trial NeOnc’s NEO100 intranasal perillyl alcohol to include additional type of brain tumor
According to NeOnc Technologies, the FDA has approved an expansion of an ongoing Phase 2a trial of the company's NEO100 intranasal perillyl alcohol to include patients with recurrent grade 3 astrocytoma with isocitrate dehydrogenase 1 (IDH1) mutation. NeOnc announced the initiation of the trial, which initially focused on treatment of grade 4 gliomas, in May 2016. The … [Read more...] about FDA allows expansion of Phase 2a trial NeOnc’s NEO100 intranasal perillyl alcohol to include additional type of brain tumor
Micromeritics to be acquired by Malvern Panalytical
Particle characterization specialist Micromeritics Instrument Corporation is set to be acquired by Spectris subsidiary Malvern Panalytical, the companies have announced. According to Spectris, the deal includes a $630 million payment up front and up to an additional $53 million on the achievement of 2024/25 performance goals. Micromeritics' products include the … [Read more...] about Micromeritics to be acquired by Malvern Panalytical
FDA completes inspection of new Kindeva analytical services facility in Minnesota
CDMO Kindeva Drug Delivery announced the completion of an FDA inspection at the company's new laboratory facility in Woodbury, MN, USA and said that the site will continue with routine cGMP audits in the future. The company announced the opening of the Woodbury facility, home to a new analytical services business unit, in January 2024. According to Kindeva, the FDA … [Read more...] about FDA completes inspection of new Kindeva analytical services facility in Minnesota
UTMB researchers publish preclinical data on intranasal mAb to prevent Tau accumulation in the brain
The University of Texas Medical Branch announced publication of an article in Science Translational Medicine by UTMB researchers who are developing an intranasal toxic tau conformation–specific monoclonal antibody-2 (TTCM2) to prevent the accumulation of tau protein in the brain. The article describes successful intranasal delivery of TTCM2 loaded in micelles to the … [Read more...] about UTMB researchers publish preclinical data on intranasal mAb to prevent Tau accumulation in the brain
Phase 1 trial FluGen’s M2SR intranasal flu vaccine in elderly demonstrated benefit of coadministration
FluGen announced that it has published data from a 2022 Phase 1 trial of its M2SR intranasal flu vaccine coadministered with Fluzone high dose intramuscular inactivated influenza vaccine (IIV) in people aged 65 to 85 in Lancet Infectious Diseases. According to the company, the study, which was funded by the US Department of Defense, demonstrated that elderly people … [Read more...] about Phase 1 trial FluGen’s M2SR intranasal flu vaccine in elderly demonstrated benefit of coadministration
Merz Therapeutics acquires Inbrija levodopa DPI from Acorda
Merz Therapeutics announced that it has acquired Inbrija inhaled dry powder levodopa from Acorda Therapeutics, which declared bankruptcy earlier this year. Merz had served as a "stalking horse bidder" for the Acorda assets, which also included Fampyra. Inbrija has been approved treatment of OFF episodes in Parkinson’s disease patients since December 2018 in the US … [Read more...] about Merz Therapeutics acquires Inbrija levodopa DPI from Acorda
Vistagen gets additional patents covering PH80 pherine nasal spray for the treatment of migraine
Vistagen announced that it has been granted patents related to the use of PH80 pherine nasal spray for the treatment of migraine in Australia, Hong Kong, Japan, and Mexico. All four of the new patents should cover PH80 through 2040. The USPTO granted a patent covering the use of PH80 for migraine in 2022, and the EPO followed in 2023. PH80 intranasal … [Read more...] about Vistagen gets additional patents covering PH80 pherine nasal spray for the treatment of migraine
Nocion announces appointments of Catherine Bonuccelli and Joan Shaw
Nocion Therapeutics, whose taplucainium (NTX-1175) DPI is in Phase 2 development for the treatment of chronic cough, has announced the appointments of two former Bellus Health executives, naming Catherine Bonuccelli to the scientific advisory board and Joan Shaw as Senior VP, Clinical Operations. Both were involved in the clinical development of Bellus' camlipixant … [Read more...] about Nocion announces appointments of Catherine Bonuccelli and Joan Shaw